Floatz logo

Sonidegib

Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8

Mayo ClinicSmall moleculePhase 1Active
CC
47/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
95/ 100

Competitive context

112 Active assets in the Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8 cohort.

Asset / SponsorPhaseRating
Irinotecan
AstraZeneca
Phase 3BBB
Cyclophosphamide
Beijing Biotech
Phase 3BB
Pembrolizumab
Eikon Therapeutics
Phase 3BB
FLUOROURACILUM
Alliance for Clinical Trials in Oncology
Phase 3BB
Capecitabine
I-Mab Biopharma US Limited
Phase 3BB

View all 50 →

Same molecule, other indications

Sonidegib is also rated in:

acute leukemiaDormant
B
Indicative ·
57 / 100
View asset →
medulloblastomaDormant
CCC
Indicative ·
54 / 100
View asset →
PTCH1 or SMO Activated Solid and Hematologic TumorsDormant
CCC
Indicative ·
53 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →